X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1745) 1745
Newsletter (77) 77
Newspaper Article (26) 26
Book Chapter (11) 11
Publication (6) 6
Magazine Article (5) 5
Dissertation (4) 4
Streaming Video (3) 3
Conference Proceeding (2) 2
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
exenatide (1663) 1663
science & technology (1121) 1121
life sciences & biomedicine (1086) 1086
humans (796) 796
type 2 diabetes (652) 652
male (581) 581
diabetes mellitus, type 2 - drug therapy (528) 528
animals (515) 515
diabetes (483) 483
endocrinology & metabolism (413) 413
female (403) 403
hypoglycemic agents - therapeutic use (397) 397
liraglutide (361) 361
peptides - therapeutic use (355) 355
peptides - pharmacology (345) 345
venoms - therapeutic use (342) 342
insulin (309) 309
venoms - pharmacology (309) 309
middle aged (308) 308
pharmacology & pharmacy (306) 306
glucagon (278) 278
peptides (272) 272
peptides - administration & dosage (256) 256
glucose (253) 253
hypoglycemic agents - administration & dosage (251) 251
venoms - administration & dosage (250) 250
diabetes mellitus (232) 232
research (226) 226
hypoglycemic agents - pharmacology (219) 219
hypoglycemic agents (209) 209
rats (202) 202
adult (200) 200
insulin - metabolism (191) 191
aged (186) 186
obesity (181) 181
hypoglycemic agents - adverse effects (180) 180
analysis (178) 178
diabetes therapy (178) 178
mice (178) 178
diabetes mellitus, type 2 - blood (176) 176
drug therapy (173) 173
glucagon-like peptide 1 (173) 173
care and treatment (171) 171
blood glucose - metabolism (167) 167
glucagon-like peptide-1 receptor (167) 167
treatment outcome (165) 165
insulin secretion (164) 164
blood glucose - drug effects (155) 155
glp-1 (153) 153
peptides - adverse effects (152) 152
internal medicine (149) 149
venoms - adverse effects (149) 149
type 2 diabetes mellitus (147) 147
glucagon-like peptide 1 - analogs & derivatives (136) 136
exendin-4 (129) 129
glucagon-like peptide-1 (126) 126
insulin resistance (126) 126
body weight (120) 120
glucagon-like peptide-1 receptor - agonists (120) 120
dextrose (119) 119
sitagliptin (114) 114
receptors, glucagon - agonists (111) 111
clinical trials (110) 110
diabetes mellitus, type 2 - metabolism (110) 110
risk factors (110) 110
glycated hemoglobin a - metabolism (108) 108
health aspects (107) 107
drug administration schedule (104) 104
dosage and administration (100) 100
general & internal medicine (100) 100
medical research (100) 100
physiological aspects (99) 99
body weight - drug effects (97) 97
drug therapy, combination (97) 97
medicine, general & internal (95) 95
rodents (95) 95
glucagon-like peptide 1 - therapeutic use (94) 94
medicine & public health (94) 94
metformin (94) 94
rats, sprague-dawley (94) 94
abridged index medicus (92) 92
medicine, research & experimental (91) 91
research & experimental medicine (91) 91
medicine, experimental (88) 88
glycosylated hemoglobin (85) 85
mice, inbred c57bl (81) 81
hypoglycemia (79) 79
diabetes mellitus, type 2 - physiopathology (78) 78
body mass index (77) 77
incretin (77) 77
glucagon-like peptide-1 receptor - metabolism (75) 75
biochemistry & molecular biology (74) 74
hyperglycemia (74) 74
peptides - pharmacokinetics (74) 74
diabetes mellitus, type 2 - complications (73) 73
dose-response relationship, drug (73) 73
endocrine system (73) 73
endocrinology (73) 73
blood sugar (72) 72
exenatide - pharmacology (72) 72
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1760) 1760
Chinese (31) 31
French (23) 23
German (21) 21
Japanese (18) 18
Spanish (16) 16
Korean (9) 9
Russian (6) 6
Czech (5) 5
Italian (4) 4
Portuguese (4) 4
Hungarian (3) 3
Turkish (3) 3
Croatian (1) 1
Danish (1) 1
Dutch (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
Medicine(all) | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Neuropsychopharmacology (New York, N.Y.), ISSN 1740-634X, 02/2018, Volume 43, Issue 10, pp. 2000 - 2008
Journal Article
Journal Article
Current diabetes reviews, ISSN 1573-3998, 2013, Volume 9, Issue 2, pp. 161 - 193
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 07/2017, Volume 19, Issue 12, pp. 1793 - 1797
The range of glycated haemoglobin (HbA1c) responses and characteristics associated with above‐average response to exenatide twice daily and once weekly were... 
predictors | exenatide twice daily | glucagon‐like peptide‐1 receptor agonist | exenatide once weekly | glucagon-like peptide-1 receptor agonist | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycated Hemoglobin A - analysis | Age Factors | Humans | Middle Aged | Diabetes Mellitus, Type 2 - metabolism | Exenatide | Peptides - administration & dosage | Hypoglycemia - prevention & control | Diabetes Mellitus, Type 2 - ethnology | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Postprandial Period | Venoms - administration & dosage | Hypoglycemia - chemically induced | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Reproducibility of Results | Drug Administration Schedule | Venoms - adverse effects | Randomized Controlled Trials as Topic | Asian Continental Ancestry Group | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Venoms - therapeutic use | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Peptides - therapeutic use | Glycosylated hemoglobin | Hypoglycemic agents | Glucagon | Analysis | Hemoglobin | Ethnicity | Regression analysis | Minority & ethnic groups | Index Medicus | Brief Report | Brief Reports
Journal Article